Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer
Cancer Research and Treatment. 2021;53(3):724-732 
Polymorphisms ofMTHFRandTYMSpredict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer
Cancer Communications. 2019;39(1):57
Hand-Foot Syndrome Variant in a Dihydropyrimidine Dehydrogenase–Deficient Patient Treated with Capecitabine
Clinical Colorectal Cancer. 2006;6(3):219-223
Capecitabine
Reactions Weekly. 2022;1890(1):77-77
Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study)
BMC Gastroenterology. 2022;22(1):
Predictors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study
. 2022;
Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome
International Journal of Cancer. 2018;142(12):2567-2577
The effect of COX-2 inhibitor on capecitabine-induced hand–foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study
Journal of Cancer Research and Clinical Oncology. 2010;137(6):953-957
Differential Diagnosis between Hand-foot Syndrome and Gout in Colorectal Cancer with Capecitabine: A Case Study and Review of the Literature
Asian Oncology Nursing. 2014;14(1):1
PP104 TYMS and DPYD polymorphisms and toxicity of 5-fluorouracil and capecitabine chemotherapy in colon cancer patients
European Journal of Cancer Supplements. 2009;7(4):20